Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
What it is
Mazdutide is a dual GLP-1 and glucagon receptor agonist. Like retatrutide it adds glucagon activity for energy expenditure on top of GLP-1's appetite suppression, but it lacks the third (GIP) receptor that retatrutide uses.
It is developed under licence by Innovent Biologics in China and Lilly elsewhere. Phase III trials are underway.
History
Originated as Lilly's OXM-3 / LY3305677. Licensed to Innovent in 2019 for the Chinese market.
How it works
GLP-1 agonism (appetite, gastric emptying) plus glucagon agonism (energy expenditure, fat oxidation).
Dosage
- Starting: 1.5 mg once weekly.
- Titration to 4–6 mg weekly over 8–12 weeks.
How it is taken
- Subcutaneous injection.
How to reconstitute
- 10 mg vial with 2 ml BAC water = 5 mg/ml. 3 mg = 60 units on a 1 ml insulin syringe.
How it should arrive
White powder, sealed vial.
How it should look once reconstituted
Clear colourless solution.
What to expect, and when
- Appetite suppression: within days.
- Weight loss: ~15% over 48 weeks in Phase II.
Side effects
- Nausea, GI side effects (typical GLP-1 profile).
- Slight elevation in heart rate at higher doses (glucagon effect).
Risks
- Pancreatitis (GLP-1 class).
- Limited long-term safety data outside trial populations.
Potential gains
- Stronger weight loss than semaglutide.
- Energy expenditure boost.
Other useful information
Less mainstream than tirzepatide or retatrutide in Western communities. Pricing is sometimes more accessible because of the Chinese-market origin.
Looking for a goal-based recommendation?
Try the Find your goal tool — answer five short questions and get peptides matched to what you actually want.